Inwood Laboratories, Inc. v. Ives Laboratories, Inc.

1982-06-01

Headline: Limits on when generic drug makers can be held responsible for pharmacists’ mislabeling, reverses an appeals court and protects manufacturers when trial findings support functional capsule colors.

Holding: The Court reversed the appeals court, holding that generic manufacturers are contributorily liable only if they intentionally induce pharmacists to mislabel or knowingly supply pharmacists who were infringing, and appellate courts must defer to trial findings unless clearly erroneous.

Real World Impact:

Protects generic manufacturers from liability absent intent or knowledge of pharmacists' mislabeling.
Requires appeals courts to accept trial judges' factual findings unless clearly erroneous.
Allows functional capsule color to be a defense in product appearance claims.

Topics: trademark law, generic drugs, pharmacist substitution, product appearance, appellate review

Summary

Background

A brand drug maker (Ives) sold cyclandelate in distinctive blue and blue-red capsules under the name CYCLOSPASMOL. After the patent expired, several generic makers sold the same medicine in identical capsule colors. Some pharmacists sometimes substituted generics and occasionally labeled them with the brand name, so Ives sued under federal trademark law claiming the generic makers had contributed to pharmacists' mislabeling.

Reasoning

The Court examined whether a drug maker can be held responsible for pharmacists’ misuse. It said a manufacturer can be liable only if it intentionally induced pharmacists to mislabel or knowingly continued to supply dealers who were actually mislabeling. The Court found the appeals court had improperly set aside the trial judge’s factual findings without showing they were clearly wrong. The trial judge had found capsule color was functional (helping patients and doctors), a finding the Court said the appeals court could not simply overturn.

Real world impact

The decision makes it harder for a brand owner to hold generic makers liable unless there is proof of intent or knowledge of specific pharmacist wrongdoing. It preserves trial judges’ factual determinations and recognizes that a functional feature like capsule color can provide a legitimate reason to copy appearance. The Court reversed the appeals court on the trademark claim and sent the case back for further review of the broader false-origin claim.

Dissents or concurrances

Two Justices concurred only in the result. Justice White agreed with reversal but warned the appeals court weakened the liability standard and argued functionality should be a full defense; Justice Rehnquist agreed reversal was required but preferred that courts of appeals usually decide whether trial findings are "clearly erroneous."